Pixantrone
Might have similar activity against aggressive lymphomas as doxorubicin, with less cardio toxicity. prnews
Related Abstracts: Pixantrone
|
Related Abstracts:
Graft vs Host | Novel
|
Graft vs Host Disease studies
.gif) |
All studies
studies for acute GvHD | chronic GvHD
Graft vs. Host Disease (GvHD) - a frequent complication of allogeneic bone marrow transplant in which the donor's bone marrow cells attacks the patient's organs and tissue. GvHD tends to be more severe in patients receiving mismatched transplants from family member and in patients receiving unrelated donor transplants. See GvHD for more detail.
TIP: After you click the query above, click
Results on Map tab to find locations of the studies in your region.
|
|
Immunotherapy
Related Abstracts:
general
vaccines
|
Immune-based studies
|
Immunotherapy without chemo or radiotherapy
| phase I for this type
|
|
CTLA4
|
|
EBV-specific lymphocyte therapy
|
|
Peripheral blood lymphocyte therapy
|
|
Immune-modulator therapy without chemotherapy
The goal of this investigative treatment type is to modify the immune system in order to fight lymphoma or enhance other treatments.
|
Lenalidomide (CC-5013, Revlimid)
Immune modulation (IMiD)
"Lenalidomide... may decrease the production of cytokine and growth factors decreasing the growth of the cells or new blood vessels for the cells. ... it could also improve the function of natural killer T cells, and enhance immunity.
Lenalidomide is currently approved by the FDA for the treatment of multiple myeloma, another type of cancer that affects circulating plasma cells, which produce antibodies. Lenalidomide is currently awaiting FDA approval for CLL and NHL."
|
Revlimid (Lenalidomide) studies
|
 Mechanisms PubMed
|
Gallium Nitrate
Ganite
|
|
Gallium Nitrate studies
The goal is induce lymphoma cell death, selectively. Trials appear to be closed as of 11/2005. Outcome data has not been presented yet.
|
|
Liposomal
Delivery of Drugs
Related Abstracts:
liposomal doxorubicin
liposomal vincristine
liposomal antisense
Topics:
Liposomal chemo
|
Liposomal Delivery of Drugs
|
Liposomal versions of biologics and chemotherapy
Liposomal delivery of treatments may reduce side effects and/or improve efficacy.
|
|
Related Abstracts:
radiotherapy
|
Radiotherapy
|
Radiotherapy all stages - Stage I | Stage II | Stage III | Stage IV
|
Excluding chemotherapy
|
|
|
Zevalin
(Y 90 Ibritumomab Tiuxetan)
and Bexxar
(iodine I 131 tositumomab)
Related Abstracts:
Radioimmunotherapy
|
Radioimmunotherapy (general)
|
All lymphoma studies utilizing radioimmunotherapy (RIT)
|
RIT studies in Canada (by request)
|
|
|
RIT for untreated lymphoma
|
|
RIT as part of Stem Cell Transplant (bitly)
|
|
RIT-based sequential therapy
Sequential therapy is following one treatment with another in order to improve on the response of the first. Also called Consolidation therapy.
|
|
Bexxar | Zevalin (two approved kinds of RIT)
|
|
DLBCL and Radioimmunotherapy
|
|
High dose, or maximum tolerated doses of treatment with RIT
|
|
Bexxar (Tositumomab, Iodine I 131)
Radioimmunotherapy for CD20 positive lymphomas.
TOPIC SEARCH: Mechanisms PubMed
|
Zevalin (approved) (90Y - Ibritumomab tiuxetan)
|
Zevalin
Radioimmunotherapy for cd20 positive lymphomas
|
TOPIC SEARCH Zevalin: Mechanisms PubMed
Also see Radio-labeled Antibodies
TIP: After you click the query above, click
Results on Map tab to find locations of the studies in your region.
|
Related Abstracts:
General - all
Allogeneic (from donor)
Non-ablative (mini)
Autologous (self)
|
Stem Cell Transplants for Lymphoma / CLL
|
All transplant studies
|
Autologous (from self) *
|
Studies exploring alternative mobilization strategies
|
|
|
Allogeneic types (from donor) *
|
|
Mini - nonmyeloablative transplants for NHL *
|
|
TIP: After you click the query above, click
Results on Map tab to find locations of the studies in your region. |
Nonmyeloablative therapy is sometimes called a mini transplant, adoptive immunotherapy, or non-ablative transplant.
With this treatment relatively low dose of chemotherapy are used to suppress the patient's immune system enough to prevent rejection of the donor cells and control the lymphoma. The pre-transplant regimen (chemo) must suppress the lymphoma sufficiently to prevent marked progression of the tumor and allow time for the Graft vs. Tumor (GVT) effect to occur -- which relies on the killing action of the donor’s immune cells to eradicate the remaining disease.
|
|
Targeted agents
|
Targeted agents
Targeted therapy is a type of medication that blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with rapidly dividing cells. Targeted cancer therapies may be more effective than current treatments and less harmful to normal cells. The main categories of targeted therapy are small molecules and monoclonal antibodies. Source: Wikipedia.org
anti-apoptosis inhibitors
Agents that target pathways in malignant cells that resist apoptosis
|
anti-apoptosis inhibitors studies:
ABT-263 | APO866 | AT-101 | GMX1777 | GX15-070 | YM155
|
Antisense (anti-bcl-2) (Oblimersen sodium, Genasense)
Antisense therapy inhibits cell production of bcl-2, a protein that is thought to inhibit cell death and increase resistance to cancer therapies. Thus, the goal of antisense therapy is to sensitize cancer cells to cancer treatments. It may also have activity as a single agent.
|
Antisense (anti-bcl-2) studies
|
TOPIC SEARCH: Mechanisms PubMed
Enzyme inhibiting therapies
Related topics: Enzyme therapy
Related Abstracts: proteasome inhibitors
|
Enzyme Inhibiting studies
|
|
Velcade (PS-341/ Bortezomib) proteasome inhibitor
|
Bortezomib for NHL (Velcade / PS-341)
(Recently approved for Multiple Myeloma and Mantle Cell Lymphoma.)
The goal of this investigative treatment type is to inhibit the breakdown of proteins in the malignant cells, which produce and require the elimination of more proteins than normal cells.
|
|
Also see Studies for Enzyme inhibitor Therapies for lymphoma
|
|
Histone deacetylase (HDAC) inhibitor
Related Abstracts: HDAC
Kinase inhibitors
|
all kinase inhibitors studies
|
tyrosine kinase inhibitor studies
|
|
Enzastaurin (LY317615), an acyclic bisindolylmaleimide, is an oral inhibitor of the protein kinase Cbeta isozyme.
|
Enzastaurin studies
|
mTOR inhibitors
"In many cancers, mTOR is inappropriately “switched on” due to the abnormal activation of one or more of the upstream signaling pathways that regulate mTOR activity. As a result, mTOR’s ability to inhibit protein synthesis and cause growth arrest when nutrients are scarce becomes compromised." Background from a sponsor: http://www.targetmtor.com
|
mTOR inhibitors for all lymphomas
|
|
Related Abstracts:
general
Idiotype-specific
|
|
Vaccines (Therapeutic) for Lymphoma
|
for CLL
|
|
for follicular Lymphoma
|
Produced by tobacco plant
|
|
|
for Mantle Cell Lymphoma
|
The goal of this investigative treatment is to educate the immune system to identify and target proteins found only on tumors.
|
|
Other New Agents
Related Abstracts:
Paclitaxel
SB-715992 - ASCO
|
Other New agents
|
CDDO
"CDDO is a novel synthetic triterpenoid which is a potent multifunctional molecule. It induces apoptosis in vitro in malignant cells through both intrinsic and extrinsic pathways, and it controls cellular differentiation, apoptosis, and growth inhibition by serving as a ligand for the transcription factor peroxisome proliferator activator receptor- gamma (PPAR gamma ). " Related articles
|
|
SB-715992
"The mitotic kinesin KSP plays an exclusive and essential role in assembly and function of the mitotic spindle. KSP represents a novel target for development of therapeutics against cancer. SB-715992 is a unique and selective inhibitor of KSP, that is preferentially overexpressed in malignant cells, functions exclusively in mitosis, and is not expressed in terminally differentiated neurons." - ASCO | Safety reports
|
|
Elsamitrucin
|
|
Paclitaxel
|
|
